Table 1.
Patient profiles of all the biopsy-proven CMV colitis cases (n = 55).
| Category | All Patients (n = 55) |
|---|---|
| Age, mean ± SD (range) (years) | 68.0 ± 15.68 (17–97) |
| Gender | |
| Male, n (%) | 28 (50.9) |
| Female, n (%) | 27 (49.1) |
| Clinical symptoms | |
| Bloody stool, n (%) | 35 (63.7) |
| Diarrhea, n (%) | 13 (23.6) |
| Abdominal pain, n (%) | 10 (18.2) |
| Fever, n (%) | 8 (14.5) |
| Lesion site | |
| Cecum, n (%) | 8 (14.5) |
| Ascending colon, n (%) | 8 (14.5) |
| Transverse colon, n (%) | 5 (9.1) |
| Descending colon, n (%) | 11 (20) |
| Sigmoid colon, n (%) | 12(21.8) |
| Rectum, n (%) | 24 (43.6) |
| Serum laboratory test | |
| N/L ration, mean ± SD | 10.80 ± 20.70 |
| Anti-CMV IgM | |
| Positive, n (%) | 3 (5.5) |
| Negative, n (%) | 22 (40) |
| Not available, n (%) | 30 (54.5) |
| Anti-CMV IgG | |
| Positive, n (%) | 21 (38.2) |
| Negative, n (%) | 0 (0) |
| Not available | 34 (61.8) |
| CMV PCR DNA amplification assays | |
| Positive, n (%) | 15 (27.3) |
| Negative, n (%) | 15 (27.3) |
| Not available, n (%) | 25 (45.4) |
| Pathology | |
| Inclusion bodies, n (%) | 32 (58.2) |
| CMV IHC staining, n (%) | 55 (100) |
| Anti-viral therapy | |
| Ganciclovir, n (%) | 17 (30.9) |
| Valganciclovir, n (%) | 12 (21.8) |
| Ganciclovir plus Valganciclovir, n (%) | 10 (18.2) |
| No treatment, n (%) | 16 (29.1) |
| Complications | |
| Perforation, n (%) | 2 (3.6) |